title: In vitro and In vivo imaging of antivasculogenesis induced by Noggin protein expression in human venous endothelial cells.
abstract: Noggin protein is a potent bone morphogenetic protein (BMP) antagonist capable of inhibiting vasculogenesis even in the presence of provasculogenic VEGF and FGF-2. We found that human umbilical vein endothelial cells (HUVECs) do not express Noggin in culture and used these cells for modeling of antivasculogenesis. We hypothesized that high-efficiency transduction of HUVECs with bicistronic lentiviral vector encoding Noggin and enhanced green fluorescent protein (EGFP) enables direct visualization of Noggin effects in homogenous primary cell populations in vitro and in vivo. By comparing HUVECs transduced with a control GFP and GFP/Noggin expression cassettes, we showed that constitutive and orthotopic Noggin protein expression did not influence cell proliferation, down-regulated BMP-2 expression, and showed no effect on BMP receptor transcripts. We demonstrated that in contrast to GFP-only control, Noggin expression in endothelial cells abrogated endothelial migration in response to monolayer injury, blocked endothelial transmigration, and caused abrogation of cord formation in vitro. Adding exogenous BMP-4 restored the formation of cords. Imaging experiments in vivo investigated vessel formation in Matrigel implants in athymic mice by utilizing GFP imaging or magnetic resonance imaging of perfusion in the implants. Both approaches demonstrated the lack of functional vessel formation after the adoptive transfer of GFP/Noggin-expressing human endothelial cells in mice.
authors.affiliation: Department of Radiology, University of Massachusetts Medical School, 55 Lake Ave. North, Worcester, MA 01655, USA.
authors.forename: Hye-Won
authors.initials: HW
authors.lastname: Kang
authors.forename: Ronn
authors.initials: R
authors.lastname: Walvick
authors.forename: Alexei
authors.initials: A
authors.lastname: Bogdanov
mesh_terms: D000818:Animals; D055396:Bone Morphogenetic Protein 2 / Q000378:metabolism; D055415:Bone Morphogenetic Protein 4 / Q000494:pharmacology; D052004:Bone Morphogenetic Protein Receptors / Q000378:metabolism; D002352:Carrier Proteins / Q000235:genetics* / Q000378:metabolism*; D002465:Cell Movement; D049109:Cell Proliferation; D002478:Cells, Cultured; D042783:Endothelial Cells / Q000378:metabolism*; D006801:Humans; D051379:Mice; D018919:Neovascularization, Physiologic / Q000502:physiology*; D014471:Umbilical Veins; D000099176:Noggin Protein
chemical_list: D055396:Bone Morphogenetic Protein 2; D055415:Bone Morphogenetic Protein 4; D052004:Bone Morphogenetic Protein Receptors; D002352:Carrier Proteins; D000099176:Noggin Protein
references.citation: Mol Cell Biol. 2003 Aug;23(16):5664-79
references.pmid: 12897139
references.citation: Clin Chem. 2003 Jan;49(1):32-40
references.pmid: 12507958
references.citation: Cytokine Growth Factor Rev. 1998 Mar;9(1):49-61
references.pmid: 9720756
references.citation: Dev Biol. 1998 May 15;197(2):205-17
references.pmid: 9630747
references.citation: J Virol Methods. 2004 Dec 15;122(2):131-9
references.pmid: 15542136
references.citation: Dev Biol. 2009 Feb 1;326(1):101-11
references.pmid: 19041859
references.citation: Mol Cancer Res. 2004 Mar;2(3):141-9
references.pmid: 15037653
references.citation: Arterioscler Thromb Vasc Biol. 2009 Feb;29(2):254-60
references.pmid: 19023092
references.citation: Pharm Res. 2007 Jun;24(6):1186-92
references.pmid: 17373582
references.citation: Am J Pathol. 2002 May;160(5):1629-37
references.pmid: 12000715
references.citation: Dev Cell. 2004 May;6(5):699-708
references.pmid: 15130494
references.citation: Bioconjug Chem. 2002 Jan-Feb;13(1):122-7
references.pmid: 11792187
references.citation: J Immunol. 2000 Jan 1;164(1):452-62
references.pmid: 10605042
references.citation: Exp Biol Med (Maywood). 2007 Jun;232(6):833-43
references.pmid: 17526776
references.citation: Mol Cell Biol. 2003 Jul;23(13):4627-36
references.pmid: 12808102
references.citation: Arterioscler Thromb Vasc Biol. 2009 May;29(5):718-24
references.pmid: 19213939
references.citation: Dev Biol. 2002 Oct 15;250(2):231-50
references.pmid: 12376100
references.citation: Nature. 2003 Mar 20;422(6929):317-22
references.pmid: 12646922
references.citation: Circulation. 2007 Sep 11;116(11):1258-66
references.pmid: 17785623
references.citation: Cancer Res. 2004 Feb 1;64(3):994-9
references.pmid: 14871830
references.citation: Nature. 2004 Mar 11;428(6979):138-9
references.pmid: 15014486
references.citation: Stem Cells. 2008 Nov;26(11):2810-20
references.pmid: 18772316
references.citation: Dev Biol. 2005 Apr 1;280(1):100-10
references.pmid: 15766751
references.citation: Ann N Y Acad Sci. 2006 Apr;1068:19-25
references.pmid: 16831902
references.citation: Cancer Res. 2005 Oct 15;65(20):9253-60
references.pmid: 16230386
references.citation: Nature. 2002 Dec 12;420(6916):636-42
references.pmid: 12478285
references.citation: Int J Cancer. 1999 Dec 10;83(6):798-802
references.pmid: 10597197
references.citation: Lab Invest. 2006 Jun;86(6):599-609
references.pmid: 16607378
references.citation: Cell. 1992 Sep 4;70(5):829-40
references.pmid: 1339313
references.citation: Klin Padiatr. 1997 Jul-Aug;209(4):265-70
references.pmid: 9293460
references.citation: J Neurosci. 2008 Sep 10;28(37):9194-204
references.pmid: 18784300